{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:16:24Z","timestamp":1788448584647,"version":"build-2803163510"},"reference-count":132,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 - AI100851"],"award-info":[{"award-number":["T32 - AI100851"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.idc.2021.03.009","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T01:24:14Z","timestamp":1621301054000},"page":"435-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["Mucormycosis"],"prefix":"10.1016","volume":"35","author":[{"given":"Julie M.","family":"Steinbrink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa H.","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/CMR.00056-10","article-title":"Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species","volume":"24","author":"Gomes","year":"2011","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CMR.13.2.236","article-title":"Zygomycetes in human disease","volume":"13","author":"Ribes","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.idc.2021.03.009_bib3","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.009_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1470-9465.2004.00843.x","article-title":"Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment","volume":"10","author":"Prabhu","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.009_bib5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A\u00a0global analysis of mucormycosis in France: the RetroZygo Study (2005-2007)","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/13693780500464930","article-title":"The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus","volume":"44","author":"Chakrabarti","year":"2006","journal-title":"Med Mycol"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib7","first-page":"106","article-title":"Updates on the taxonomy of mucorales with an emphasis on clinically important taxa","volume":"5","author":"Walther","year":"2019","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/mr.55.2.234-258.1991","article-title":"Mucor dimorphism","volume":"55","author":"Orlowski","year":"1991","journal-title":"Microbiol Rev"},{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.FUNK-0034-2016","article-title":"Cell biology of hyphal growth","volume":"5","author":"Steinberg","year":"2017","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.idc.2021.03.009_bib11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006","volume":"17","author":"Park","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2012.06.012","article-title":"The PATH (Prospective Antifungal Therapy) Alliance\u00ae registry and invasive fungal infections: update 2012","volume":"73","author":"Azie","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12879-016-2023-z","article-title":"Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study","volume":"16","author":"Kontoyiannis","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2021.03.009_bib14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1086\/319985","article-title":"Invasive mold infections in allogeneic bone marrow transplant recipients","volume":"32","author":"Baddley","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.009_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","article-title":"Zygomycosis in the 1990s in a tertiary-care cancer center","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2021.03.009_bib16","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/j.1600-6143.2006.01496.x","article-title":"Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature","volume":"6","author":"Almyroudis","year":"2006","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J\u00a0Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2021.03.009_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cis195","article-title":"Mucormycosis in organ and stem cell transplant recipients","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.009_bib21","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-0039-3401992","article-title":"Mucormycosis","volume":"41","author":"Reid","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.idc.2021.03.009_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy","volume":"39","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transpl"},{"issue":"9462","key":"10.1016\/j.idc.2021.03.009_bib24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0140-6736(05)71046-1","article-title":"Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka","volume":"365","author":"Andresen","year":"2005","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.idc.2021.03.009_bib25","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1056\/NEJMoa1204781","article-title":"Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011","volume":"367","author":"Neblett Fanfair","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.idc.2021.03.009_bib26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/cid\/cis749","article-title":"Invasive mold infections following combat-related injuries","volume":"55","author":"Warkentien","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.009_bib27","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/cid\/cir867","article-title":"Healthcare-associated mucormycosis","volume":"54","author":"Rammaert","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib28","first-page":"69","article-title":"A\u00a0guide to investigating suspected outbreaks of mucormycosis in healthcare","volume":"5","author":"Hartnett","year":"2019","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"6","key":"10.1016\/j.idc.2021.03.009_bib29","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.clinthera.2018.03.009","article-title":"Recent advances in the pathogenesis of mucormycoses","volume":"40","author":"Petrikkos","year":"2018","journal-title":"Clin Ther"},{"issue":"Supplement_2","key":"10.1016\/j.idc.2021.03.009_bib30","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1093\/mmy\/myz011","article-title":"Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors","volume":"57","author":"Hassan","year":"2019","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib31","first-page":"169","article-title":"Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene","volume":"235","author":"Fu","year":"2004","journal-title":"FEMS Microbiol Lett"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1172\/JCI71349","article-title":"CotH3 mediates fungal invasion of host cells during mucormycosis","volume":"124","author":"Gebremariam","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00294-017-0798-0","article-title":"Control of morphology and virulence by ADP-ribosylation factors (Arf) in Mucor circinelloides","volume":"64","author":"Pati\u00f1o-Medina","year":"2018","journal-title":"Curr Genet"},{"issue":"9398","key":"10.1016\/j.idc.2021.03.009_bib34","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"issue":"Suppl 6","key":"10.1016\/j.idc.2021.03.009_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/1469-0691.12566","article-title":"Mucormycosis\u2013from the pathogens to the disease","volume":"20","author":"Binder","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.idc.2021.03.009_bib36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tim.2009.09.003","article-title":"Endofungal bacteria as producers of mycotoxins","volume":"17","author":"Lackner","year":"2009","journal-title":"Trends Microbiol"},{"issue":"7060","key":"10.1016\/j.idc.2021.03.009_bib37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nature03997","article-title":"Pathogenic fungus harbours endosymbiotic bacteria for toxin production","volume":"437","author":"Partida-Martinez","year":"2005","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.idc.2021.03.009_bib38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1086\/597615","article-title":"Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis","volume":"199","author":"Lamaris","year":"2009","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib39","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4161\/viru.2.4.17074","article-title":"Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection","volume":"2","author":"Lewis","year":"2011","journal-title":"Virulence"},{"issue":"5","key":"10.1016\/j.idc.2021.03.009_bib40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1177\/0194599816658024","article-title":"Rhinocerebral mucormycosis of the optic nerve","volume":"155","author":"Mattingly","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"10 Pt 1","key":"10.1016\/j.idc.2021.03.009_bib41","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1288\/00005537-198910000-00006","article-title":"Rhinocerebral mucormycosis: predisposing factors","volume":"92","author":"McNulty","year":"1982","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/TP.0b013e3181dde8fc","article-title":"Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients","volume":"90","author":"Sun","year":"2010","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.idc.2021.03.009_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1469-0691.2009.02884.x","article-title":"Rhinocerebral mucormycosis in patients without predisposing medical conditions: a review of the literature","volume":"15","author":"Elinav","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.idc.2021.03.009_bib44","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/00005537-199610000-00024","article-title":"Chronic rhinocerebral mucormycosis","volume":"106","author":"Harrill","year":"1996","journal-title":"Laryngoscope"},{"issue":"6","key":"10.1016\/j.idc.2021.03.009_bib45","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/coa.13175","article-title":"A\u00a0meta-analysis of survival factors in rhino-orbital-cerebral mucormycosis-has anything changed in the past 20 years?","volume":"43","author":"Vaughan","year":"2018","journal-title":"Clin Otolaryngol"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0039-6257(05)80041-4","article-title":"Survival factors in rhino-orbital-cerebral mucormycosis","volume":"39","author":"Yohai","year":"1994","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"10.1016\/j.idc.2021.03.009_bib47","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/00007611-199410000-00006","article-title":"Isolated central nervous system mucormycosis","volume":"87","author":"Siddiqi","year":"1994","journal-title":"Southampt Med J"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00042560-199512000-00007","article-title":"Zygomycosis (mucormycosis) and HIV infection: report of three cases and review","volume":"10","author":"Nagy-Agren","year":"1995","journal-title":"J\u00a0Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s15010-018-1149-x","article-title":"Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome","volume":"46","author":"Feng","year":"2018","journal-title":"Infection"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1378\/chest.75.4.524","article-title":"Mucor mediastinitis","volume":"75","author":"Connor","year":"1979","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.idc.2021.03.009_bib51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1055\/s-0031-1295717","article-title":"Pulmonary mucormycosis","volume":"32","author":"Hamilos","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib52","article-title":"Global epidemiology of Mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2021.03.009_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1469-0691.2009.02979.x","article-title":"Cutaneous zygomycosis","volume":"15","author":"Skiada","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.idc.2021.03.009_bib54","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1128\/JCM.00908-09","article-title":"Outbreak of intestinal infection due to Rhizopus microsporus","volume":"47","author":"Cheng","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"issue":"16","key":"10.1016\/j.idc.2021.03.009_bib55","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJMcpc1208153","article-title":"Case records of the Massachusetts General Hospital. Case 32-2013. A 55-year-old woman with autoimmune hepatitis, cirrhosis, anorexia, and abdominal pain","volume":"369","author":"Corey","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007611-199703000-00017","article-title":"Nonfatal gastric mucormycosis in a renal transplant recipient","volume":"90","author":"Martinez","year":"1997","journal-title":"Southampt Med J"},{"issue":"12","key":"10.1016\/j.idc.2021.03.009_bib57","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1681\/ASN.V5122014","article-title":"Isolated renal mucormycosis: case report and review","volume":"5","author":"Levy","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib58","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/514562","article-title":"Successful medical management of isolated renal zygomycosis: case report and review","volume":"26","author":"Weng","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib59","first-page":"181","article-title":"The burden of mucormycosis in HIV-infected patients: a systematic review","volume":"73","author":"Moreira","year":"2016","journal-title":"J\u00a0Infect"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.009_bib60","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/cid\/cir868","article-title":"Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)","volume":"54","author":"Walsh","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.009_bib61","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","article-title":"Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer","volume":"41","author":"Chamilos","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2021.03.009_bib63","doi-asserted-by":"crossref","first-page":"684.e11","DOI":"10.1016\/j.cmi.2015.03.019","article-title":"Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis","volume":"21","author":"Jung","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib64","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2214\/AJR.17.18792","article-title":"Pulmonary mucormycosis: radiologic features at presentation and over time","volume":"210","author":"Hammer","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.idc.2021.03.009_bib65","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/432470","article-title":"Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans","volume":"41","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2021.03.009_bib66","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1055\/s-0035-1562892","article-title":"Role of non-culture-based tests, with an emphasis on galactomannan testing for the diagnosis of invasive aspergillosis","volume":"36","author":"Miceli","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.idc.2021.03.009_bib67","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2021.03.009_bib68","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/jcp.2004.024703","article-title":"PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue","volume":"58","author":"Bialek","year":"2005","journal-title":"J\u00a0Clin Pathol"},{"issue":"6","key":"10.1016\/j.idc.2021.03.009_bib69","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1128\/JCM.00256-11","article-title":"Molecular methods to improve diagnosis and identification of mucormycosis","volume":"49","author":"Hammond","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.idc.2021.03.009_bib70","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fgene.2020.00699","article-title":"Understanding mucormycoses in the age of \"omics\"","volume":"11","author":"Soare","year":"2020","journal-title":"Front Genet"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib71","first-page":"265","article-title":"Epidemiology and diagnosis of mucormycosis: an update","volume":"6","author":"Skiada","year":"2020","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.idc.2021.03.009_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.02.005","article-title":"A\u00a0transcriptional signature accurately identifies Aspergillus infection across healthy and immunosuppressed states","volume":"219","author":"Steinbrink","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.idc.2021.03.009_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mmcr.2020.02.003","article-title":"The robust and rapid role of molecular testing in precision fungal diagnostics: a case report","volume":"27","author":"Steinbrink","year":"2020","journal-title":"Med Mycol Case Rep"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.009_bib74","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1093\/ofid\/ofx162.124","article-title":"Breath-based diagnosis of invasive mucormycosis (IM)","volume":"4","author":"Koshy","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.03.009_bib76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2009.02984.x","article-title":"In\u00a0vitro activity of antifungals against zygomycetes","volume":"15","author":"Alastruey-Izquierdo","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In\u00a0vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"Dannaoui","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib78","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMra1216008","article-title":"Mold infections of the central nervous system","volume":"371","author":"McCarthy","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib79","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/JCM.06133-11","article-title":"Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales","volume":"50","author":"Vitale","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.idc.2021.03.009_bib80","first-page":"9","article-title":"Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients","volume":"5","author":"Miceli","year":"2012","journal-title":"Infect Drug Resist"},{"issue":"12","key":"10.1016\/j.idc.2021.03.009_bib81","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib82","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","article-title":"Forty-one recent cases of invasive zygomycosis from a global clinical registry","volume":"65","author":"R\u00fcping","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2021.03.009_bib83","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1469-0691.2009.02987.x","article-title":"Lipid formulations of amphotericin B as first-line treatment of zygomycosis","volume":"15","author":"Petrikkos","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib84","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1399-3062.2006.00197.x","article-title":"Outcomes of invasive zygomycosis infections in renal transplant recipients","volume":"9","author":"Forrest","year":"2007","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2021.03.009_bib85","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10\u00a0mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib86","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.04435-14","article-title":"Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrobial Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib87","first-page":"DD01","article-title":"Amphotericin B resistant apophysomyces elegans causing rhino-oculo-cerebral mucormycosis in an immunocompetent host","volume":"9","author":"Biswas","year":"2015","journal-title":"J\u00a0Clin Diagn Res"},{"issue":"4","key":"10.1016\/j.idc.2021.03.009_bib88","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In\u00a0vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrobial Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib89","first-page":"272","article-title":"In\u00a0vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries","volume":"21","author":"Verweij","year":"2009","journal-title":"J\u00a0Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib90","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/AAC.01539-06","article-title":"In\u00a0vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest","volume":"51","author":"Torres-Narbona","year":"2007","journal-title":"Antimicrobial Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2021.03.009_bib91","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: a broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib92","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrobial Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.009_bib93","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2021.03.009_bib94","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrobial Agents Chemother"},{"issue":"11","key":"10.1016\/j.idc.2021.03.009_bib95","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A\u00a0new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.idc.2021.03.009_bib96","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrobial Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib97","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/jac\/dkx122","article-title":"Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation","volume":"72","author":"Pettit","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2021.03.009_bib98","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/ajt.13186","article-title":"Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients","volume":"15","author":"Farmakiotis","year":"2015","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.idc.2021.03.009_bib99","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/myc.12339","article-title":"Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis","volume":"58","author":"Miceli","year":"2015","journal-title":"Mycoses"},{"issue":"10","key":"10.1016\/j.idc.2021.03.009_bib100","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkx228","article-title":"Risk factors for subtherapeutic levels of posaconazole tablet","volume":"72","author":"Tang","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib101","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00188-17","article-title":"Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses","volume":"61","author":"Tverdek","year":"2017","journal-title":"Antimicrobial Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2021.03.009_bib102","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.009_bib103","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1093\/ofid\/ofu052.532","article-title":"824: an open-label phase 3 study of Isavuconazole (VITAL): focus on mucormycosis","volume":"1","author":"Marty","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2021.03.009_bib104","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib105","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JCM.03176-13","article-title":"Isavuconazole treatment of a patient with disseminated mucormycosis","volume":"52","author":"Peixoto","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib106","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s15010-013-0552-6","article-title":"Successful isavuconazole salvage therapy in a patient with invasive mucormycosis","volume":"42","author":"Ervens","year":"2014","journal-title":"Infection"},{"issue":"9","key":"10.1016\/j.idc.2021.03.009_bib107","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3201\/eid2509.190598","article-title":"Invasive fungal disease, isavuconazole treatment failure, and death in acute myeloid leukemia patients","volume":"25","author":"Bellanger","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2021.03.009_bib108","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijantimicag.2017.08.010","article-title":"Antifungal resistance in mucorales","volume":"50","author":"Dannaoui","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.idc.2021.03.009_bib109","first-page":"8","article-title":"Isavuconazole: a new broad-spectrum azole. Part 1: in\u00a0vitro activity","volume":"28","author":"Denis","year":"2018","journal-title":"J\u00a0Mycol Med"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib110","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib111","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/1040841X.2012.711741","article-title":"Mucormycosis treated with posaconazole: review of 96 case reports","volume":"39","author":"Vehreschild","year":"2013","journal-title":"Crit Rev Microbiol"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2021.03.009_bib112","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1469-0691.2009.02985.x","article-title":"Current experience in treating invasive zygomycosis with posaconazole","volume":"15","author":"Cornely","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.idc.2021.03.009_bib113","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.idc.2021.03.009_bib114","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrobial Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.009_bib115","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what, and how?","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib116","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib117","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s10096-002-0781-6","article-title":"Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B.","volume":"21","author":"Voitl","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2021.03.009_bib118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mmcr.2015.03.003","article-title":"How should we manage a patient with invasive mucoromycosis who develops life-threatening reaction to amphotericin B? Report of two cases and literature review","volume":"8","author":"Sheybani","year":"2015","journal-title":"Med Mycol Case Rep"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2021.03.009_bib119","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.idc.2021.03.009_bib120","doi-asserted-by":"crossref","first-page":"O336","DOI":"10.1111\/1469-0691.12408","article-title":"Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival","volume":"20","author":"Vironneau","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib121","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: pathophysiology, presentation, and management","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2021.03.009_bib122","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1469-0691.2009.02989.x","article-title":"Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon","volume":"15","author":"Rapidis","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.idc.2021.03.009_bib123","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1086\/320767","article-title":"Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor","volume":"32","author":"Garcia-Diaz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2021.03.009_bib124","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.inf.0000134314.65398.bf","article-title":"Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children","volume":"23","author":"Abzug","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.idc.2021.03.009_bib125","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3109\/10428190109097768","article-title":"Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF","volume":"42","author":"Ma","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.idc.2021.03.009_bib126","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron chelator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","author":"Ibrahim","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.idc.2021.03.009_bib127","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.01065-06","article-title":"Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis","volume":"50","author":"Reed","year":"2006","journal-title":"Antimicrobial Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.009_bib128","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.00361-09","article-title":"Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis","volume":"53","author":"Spellberg","year":"2009","journal-title":"Antimicrobial Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.009_bib129","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.009_bib130","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1469-0691.2005.01170.x","article-title":"Hyperbaric oxygen as an adjunctive treatment for zygomycosis","volume":"11","author":"John","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 5","key":"10.1016\/j.idc.2021.03.009_bib131","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1469-0691.2009.02986.x","article-title":"Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis","volume":"15","author":"Tragiannidis","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.idc.2021.03.009_bib132","first-page":"355","article-title":"Hyperbaric oxygen in the treatment of invasive fungal infections: a single-center experience","volume":"9","author":"Segal","year":"2007","journal-title":"Isr Med Assoc J"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552021000192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552021000192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:31:16Z","timestamp":1760196676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552021000192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0891552021000192"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2021.03.009","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucormycosis","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2021.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}